Accretion PharmaceuticalsNSE:ACCPL -1.81%18 Net Margin % is 10.71% as of Mar. 2026, which is 1% below its 10-year median of 10.79. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 66.21% on this metric.
The historical rank and industry rank for Accretion Pharmaceuticals's Net Margin % or its related term are showing as below:
NSE:ACCPL'
s Net Margin % Range Over the Past 10 Years
Min: 0.35 Med: 10.79 Max: 11.84
Current: 10.79
NSE:ACCPL's Net Margin % is ranked better than 66.21% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:ACCPL: 10.79
Accretion Pharmaceuticals (NSE:ACCPL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Accretion Pharmaceuticals Net Margin % Related Terms
Accretion Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a Net Margin % of 10.71% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Accretion Pharmaceuticals and its competitors. This is near median its historical median of 10.79. Over the past decade, Accretion Pharmaceuticals' Net Margin % has ranged from 0.35 to 11.84. According to the industry distribution chart, Accretion Pharmaceuticals ranks #323 out of 956 companies in the Drug Manufacturers industry, placing it in the top 33.8%.
Is Accretion Pharmaceuticals' Net Margin % too high?
Accretion Pharmaceuticals' current Net Margin % of 10.71% is near median its 10-year median of 10.79. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 11.84. The Drug Manufacturers industry median Net Margin % is 5.56. Accretion Pharmaceuticals' value of 10.71% is 92.6% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #323 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #323 out of 956 companies for Net Margin %. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Net Margin % is 5.56. Accretion Pharmaceuticals' value of 10.71% is 92.6% above this benchmark. Historically, Accretion Pharmaceuticals' own Net Margin % has ranged from 0.35 to 11.84 over the past decade. While the company's 10-year median is 10.79 vs. the industry median of 5.56, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Net Margin % of 10.71% is 92.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Net Margin % is 10.71%, which is near median its own 10-year median of 10.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Net Margin % of 10.71%. The current Net Margin % is 10.71%, which is near median its 10-year median of 10.79 and 92.6% above the Drug Manufacturers industry median of 5.56. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Net Margin % is 10.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 